The recovery of a kidney transplant recipient from COVID-19 has provided insight into the treatment of immunosuppressed coronavirus patients.
NuVasive, Inc. (Nasdaq: NUVA) has announced a recent publication demonstrating the efficacy of their synthetic bioactive putty in lumbar fusion.
Limited Efficacy of Immunosuppressive Strategy in Transplant Patients Associated with Immunoproteosome
The limited efficacy of a proteosome inhibitor-based immunosuppressive strategy in highly HLA-sensitized transplant recipients has been associated with the immunoproteosome.
A therapy for steroid-refractory and/or resistant GvHD may function by favorably altering a population of circulating white blood cells.
The expression level of the protein Interleukin-21 in circulating immune cells may serve as a biomarker for kidney transplant rejection.
Possible Combination Therapy for Sensitized Kidney Transplant Recipients Harnesses Existing Cancer Drug
A combinationm therapy involving an existing cancer drug and costimulation blockade has shown promise for sensitized kidney transplant recipients.
A cell surface receptor for a protein associated with the innate immune system known as a complement receptor has recently been demonstrated to be important for the prevention of heart transplant rejection in mice.